Did You Suffer Permanent Hair Loss After Using This Drug?
Taxotere, also known as docetaxel, is used by countless patients suffering from breast cancer in the United States. This chemotherapy drug produced by Sanofi is widely used due to its convenience – the leading competitor, paclitaxel, needs to be taken once per week while patients only need to take Taxotere once every three weeks. Its widespread use allowed Sanofi to reportedly make more than $3 billion in sales before they lost patent protection in 2009.
If you suffered from Taxotere’s hidden side effect, call us at (866) 977-6671 today to discuss your situation with a member of our firm.
While Taxotere may be a common way to treat cancer, it comes with a considerable side effect – according to studies, about nine percent of patients who take this drug suffer from permanent hair loss, also known as alopecia, for 10 years or more. This hair loss caused negative body image, depression, distress and a noticeable decrease in the quality of their lives. Despite all this, Sanofi failed to inform people of the potential side effect and hid their own research that linked their product to alopecia.
Sanofi Failed To Report These Side Effects
Taxotere only received a label change order from the United States Food and Drug Administration (FDA) in December of 2015, years after the first reports linking the product to alopecia were first published.
- Researchers presented their study linking Taxotere to long-term hair loss at the 2014 NCRI Cancer Conference. Patients involved in the study who took docetaxel received a questionnaire about any hair loss and approximately 16 percent of those who responded stated that they dealt with persistent and significant alopecia anywhere from their eyebrows to their legs to their head.
- Back in 2012, the Annals of Oncology published a study (PDF) that linked Taxotere to a heightened risk of developing alopecia. During the study, researchers found that out of their 20 subjects, the women who took docetaxel had an increased chance of severe and permanent hair loss that could not be properly treated through vitamins, minoxidil, psoralen, spironolactone, and ultraviolet A therapy.
- Sanofi published an internal study in the New England Journal of Medicine in 2005 listing hair loss as a common side effect of their own product.
Approximately 3 million people have a history of breast cancer in the United States, and while hair loss is a common side effect of chemotherapy, it should grow back once treatment stops. Because Sanofi hid this permanently disfiguring side effect from the general public, they have caused considerable harm to countless cancer survivors.
Hire An Experienced Lawyer Today
With more than 170 years of combined experience, our defective drug lawyers at Fleming, Nolen & Jez have the knowledge you need to fight for and secure the legal outcome you deserve. Give us a call at (866) 977-6671 to discuss your situation with a member of our firm today, or send us your information through our online form to request a free consultation.